FDA's Proposed Shift Away from Expert Drug Reviews

FDA's Proposed Policy Change

• 💊 The FDA is considering a significant shift away from its long-standing policy of utilizing outside expert panels to review new drug applications.
• 🗓️ These external committees have been a crucial part of the FDA's decision-making process since the 1970s, offering specialized scientific and clinical advice.

Rationale Behind the Move

• 💡 The new head of the FDA's drugs division, George Tidmar, explained that the agency believes these committees are redundant.
• 📄 Tidmar suggested that the public will gain sufficient understanding from the FDA's released letters when drug applications are turned down.
• ❓ However, individuals interviewed believe this comparison is flawed and question the reasoning behind abandoning expert reviews.

Importance of Expert Panels

• 📈 Expert panels have historically played an enormously influential role in balancing the push for faster drug approval with the critical need for drug safety.
• ⚖️ These committees provided a space to evaluate drugs that might have benefits but also potential downsides, offering advice on whether to proceed.
• ✅ While the FDA was not obligated to follow their recommendations and sometimes overruled them, they often aligned with the advisory committee's suggestions.